drugset / Trial / NCT07052565
CAR-T Cells Therapy for Patients With Autoimmune Diseases
NaSequentialOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Timeline
- Start
- 2025-07-20
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ECAR01 | Cell therapy | 1 cells/kg | Intravenous |
| Subject | ECAR01 | Cell therapy | 3 cells/kg | Intravenous |
| Subject | ECAR01 | Cell therapy | 6 cells/kg | Intravenous |